Study Supports the Company's Treatment Strategy
Wednesday September 6, 8:31 am Eastern Time
WOODLAND HILLS, Calif.--(BUSINESS WIRE)--Sept. 6, 2000--Advanced Biotherapy, Inc. (OTCBB:ADVB - news), announced today the results of a 60 patient randomized, double blind, placebo controlled clinical trial evaluating the efficacy of its proprietary Anti-interferon-gamma drug (Anti-IFNg), for the treatment of Secondary Progressive Multiple Sclerosis (MS) patients. The results showed statistically significant improvements, at both six and 12 months after treatment, when compared to both the placebo group and the group treated with Anti-Tumor necrosis factor-alpha (Anti-TNFa).
The trial was conducted at the Russian State Medical University, in Moscow, Russia. Drug treatments were administered twice daily for five days and an extensive battery of clinical indices of disease progression were evaluated for a period of one year post-treatment. The parameters evaluated included Functional and Disability scores, Magnetic Resonance Imaging (MRI), Evoked Potentials and various biochemical indices. The 15 patients in the Anti-IFNg group, had statistically significantly better outcomes at both six and 12 months treatment when compared to either the 15 patients receiving a Placebo, 15 patients receiving Anti-TNFa, or the 15 patients treated with both antibodies.
Commenting on the results, Dr. Paul J. Marangos, Chairman and CEO of Advanced Biotherapy, Inc. stated, ``We are very pleased about the results of this study demonstrating the superiority of our proprietary Anti-IFNg approach for treating MS patients when compared to Anti-TNFa.'' He added, ``This study positions us favorably for the continued development of this product.''
Advanced Biotherapy, Inc. is developing proprietary treatments for a range of autoimmune diseases, including Rheumatoid Arthritis, Multiple Sclerosis, Type I Diabetes and AIDS. The company's drugs neutralize immunomodulators called Cytokines, which have now been shown to be linked to these diseases.
Statements made in this release, other than statements of historical fact, are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the results of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of the company's patent portfolio. See the company's public filings with the Securities and Exchange Commission for information about risks that may affect the company.
Advanced Biotherapy Inc., Woodland Hills
Edmond Buccellato, 818/883-3956